title: A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
abstract: This article informs the reader of the current information available on a novel therapeutic agent and new class of drug for the treatment of anemia. The data show promising results for alternative erythropoietin-stimulating agents and offers a time line of when Phase III data will be available. The information on this new drug and new drug class will change how nephrologists approach treating anemia within their patients.
authors.affiliation: St. John's University, Jamaica, NY, USA. kimberly.anne.becker@gmail.com.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Becker
authors.affiliation: St. John's University, Jamaica, NY, USA.
authors.forename: Maha
authors.initials: M
authors.lastname: Saad
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D005998:Glycine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D006397:Hematinics; D007546:Isoquinolines; D005998:Glycine; C584543:roxadustat
keywords: Anemia; Chronic kidney disease; Dialysis; Erythropoietin-stimulating agent; HIF-Inhibitor; Hematology; Hemoglobin; Nephrology; Non-dialysis; Roxadustat